KCL-HO-1i
KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor (rat HO-1: IC50 = 123 nM) and human HO-1: IC50 = 128 nM) . KCL-HO-1i targets immunosuppressive LYVE-1+ perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME), reduces PvTAM-mediated immune exclusion. KCL-HO-1i demonstrates synergistic anti-tumor efficacy with chemotherapy in MMTV-PyMT spontaneous breast cancer mice or C57Bl/6 mice bearing subcutaneous MN-MCA1 sarcomas. KCL-HO-1i can be used for the study of cancer[1].
Product Specifications
UNSPSC
12352100
Target
Heme Oxygenase (HO)
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
CCC1=C(C)C2=N/C1=C\C3=C(C)C(CC)=C4N3[Sn](OP([O-])([O-])=O)(OP([O-])([O-])=O)N(/C(C(C)=C/5CCC(O)=O)=C\2)C5=C/C6=N/C(C(C)=C6CCC(O)=O)=C\4.[Sn+2].[Sn+2]
Molecular Formula
C34H36N4O12P2Sn3
Molecular Weight
1110.75
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HO-1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Rbl1 (NM_011249) Mouse Tagged ORF Clone Lentiviral Particle
Prim2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)